Lonza Group AG

LONN

CH0013841017

Biotechnology & Medical Research

Market Closed - Swiss Exchange Other stock markets 10:01:29 06/02/2026 pm IST			5-day change	1st Jan Change
517.20 ^CHF	-0.19%		-1.49%	-3.83%

03/02	Swiss stocks - Factors to watch on February 3	RE
29/01	Swiss trade surplus at CHF 1.036 bln in December	RE

Lonza Group confirms full year 2025 outlook for CDMO and CHI businesses

Published on 10/23/2025 at 11:08 am IST

Reuters

Latest news about Lonza Group AG

03/02	Swiss stocks - Factors to watch on February 3	RE
29/01	Swiss trade surplus at CHF 1.036 bln in December	RE
28/01	Glum Economic Sentiment Weighs on Swiss Stocks; All Eyes on US Rate Decision	MT
28/01	Global markets live: Amazon, Bank of America, Oracle, Eli Lilly, Boeing…
28/01	Lonza Group AG, 2025 Earnings Call, Jan 28, 2026
28/01	LONZA GROUP : Ended 2025 on a high note
28/01	Lonza Group Forecasts Sustained Growth in 2026 After Sales Beat	MT
28/01	Switzerland's Lonza edges closer to sale of its capsule and health ingredients business (Jan. 28)	RE
28/01	Lonza Group AG Reports Earnings Results for the Full Year Ended December 31, 2025	CI
28/01	Lonza's Attributable Profit Rises in 2025	MT
28/01	Contract drug manufacturer Lonza forecasts slower sales growth for 2026	RE
28/01	Lonza Sales Grow on New Contract Momentum	DJ
28/01	Lonza Group's FY25 Profit, Sales Rise	MT
28/01	Swiss stocks - Factors to watch on January 28	RE
28/01	Lonza FY Sales Growth 21.7%	RE
28/01	Lonza forecasts 2026 sales growth of 11-12% for core CDMO business	RE
28/01	Lonza Group AG Proposes Dividend for 2025	CI
28/01	Lonza Group AG Provides Earnings Guidance for 2026	CI
14/01	Lonza Group AG Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 10:30 AM
18/12	Swiss trade surplus at CHF 3.841 bln in November	RE
10/12	The Berkeley Group Holdings plc Appoints Barbara Richmond as Independent Non-Executive Board Director, Effective 1 January 2026	CI
25/11	Morgan Stanley Upgrades Lonza Group to Overweight, Lifts PT	MT
24/11	Microsize, Inc. and Schedio SA signed an agreement to acquire Micro-Macinazione S.A. from Lonza Group AG.	CI
24/11	Microsize, Inc. and Schedio SA signed an agreement to acquire Micro-Macinazione S.A. from Lonza Group AG.	CI
20/11	Swiss trade surplus at CHF 4.32 bln in October	RE

Lonza Group AG is one of the world leaders of the contract development and manufacturing of pharmaceutical and biotechnology products. Net sales break down by family of products and services as follows: - biologics and bio-pharmaceuticals (55.9%): microbiological fermentation products, mammalian cell-based bio-pharmaceuticals, monoclonal antibodies, therapeutic proteins, etc.; - synthesis products (24.7%): chemopharmaceutical products, bioconjugates, small molecules, active pharmaceutical ingredients, complex intermediates, etc.; - specialised therapeutic products (15.8%): cell and gene therapies, synthetic therapeutic nucleic acids, oligonucleotides, microbial biological products, etc.; - others (3.6%).

Employees

19,771

Sector

Biotechnology & Medical Research

Calendar

09/02/2026 - Phacilitate Advanced Therapies Week

More about the company